TY - JOUR
T1 - Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment
T2 - A European Alzheimer's Disease Consortium survey
AU - Frederiksen, Kristian S.
AU - Nielsen, Thomas R.
AU - Appollonio, Ildebrando
AU - Andersen, Birgitte Bo
AU - Riverol, Mario
AU - Boada, Mercè
AU - Ceccaldi, Mathieu
AU - Dubois, Bruno
AU - Engelborghs, Sebastiaan
AU - Frölich, Lutz
AU - Hausner, Lucrezia
AU - Gabelle, Audrey
AU - Gabryelewicz, Tomasz
AU - Grimmer, Timo
AU - Hanseeuw, Bernard
AU - Hort, Jakub
AU - Hugon, Jacques
AU - Jelic, Vesna
AU - Koivisto, Anne
AU - Kramberger, Milica G.
AU - Lebouvier, Thibaud
AU - Lleó, Alberto
AU - de Mendonça, Alexandre
AU - Nobili, Flavio
AU - Ousset, Pierre-Jean
AU - Perneczky, Robert
AU - Olde Rikkert, Marcel
AU - Robinson, David
AU - Rouaud, Olivier
AU - Sánchez, Elisabet
AU - Santana, Isabel
AU - Scarmeas, Nikolaos
AU - Sheardova, Katerina
AU - Sloan, Stephanie
AU - Spiru, Luiza
AU - Stefanova, Elka
AU - Traykov, Latchezar
AU - Yener, Görsev
AU - Waldemar, Gunhild
N1 - Funding Information:
Kristian S. Frederiksen, T Rune Nielsen, Ildebrando Appollonio, Birgitte Bo Andersen, Mario Riverol, Mercè Boada, Mathieu Ceccaldi, Bruno Dubois, Sebastiaan Engelborghs, Lutz Frölich, Lucrezia Hausner, Audrey Gabelle, Tomasz Gabryelewicz, Bernard Hanseeuw, Jakub Hort, Jacques Hugon, Vesna Jelic Anne Koivisto, Milica G. Kramberger, Thibaud Lebouvier, Alberto Lleó, Alexandre de Mendonça, Flavio Nobili, Pierre‐Jean Ousset, Robert Perneczky, Marcel Olde Rikkert, David Robinson, Olivier Rouaud, Elisabet Sánchez, Isabel Santana, Katerina Sheardova, Stephanie Sloan, Luiza Spiru, Elka Stefanova, Latchezar Traykov, Görsev Yener, Gunhild Waldemar have no conflicts of interest regarding this manuscript. Outside the submitted work Dr. Grimmer reported having received consulting fees from Actelion, Biogen, Eli Lilly, Iqvia/Quintiles; MSD; Novartis, Quintiles, Roche Pharma, lecture fees from Biogen, Lilly, Parexel, Roche Pharma, and grants to his institution from Actelion and PreDemTech. Outside the submitted work Dr. Scarmeas reports grants from Alzheimer's Association, grants from European Social Fund, grants from Ministry for Health Greece, during the conduct of the study; personal fees from Merck Consumer Health, personal fees from NIH, grants from EISAI, personal fees from EISAI Korea, grants from EPAD.
Publisher Copyright:
© 2020 John Wiley & Sons Ltd.
PY - 2021/2
Y1 - 2021/2
N2 - Objectives: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counseling, management, and follow-up in European expert centers diagnosing patients with MCI.Methods: An online email survey was distributed to physicians affiliated with European Alzheimer's disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; and Southern Europe: 15 centers) with questions on attitudes toward biomarkers and biomarker counseling in MCI and dementia. This included postbiomarker counseling and the process of diagnostic disclosure of MCI, as well as treatment and follow-up in MCI.Results: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre- and postbiomarker counseling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI.Conclusions: The variability in clinical practices across centers calls for better biomarker counseling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning.
AB - Objectives: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counseling, management, and follow-up in European expert centers diagnosing patients with MCI.Methods: An online email survey was distributed to physicians affiliated with European Alzheimer's disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; and Southern Europe: 15 centers) with questions on attitudes toward biomarkers and biomarker counseling in MCI and dementia. This included postbiomarker counseling and the process of diagnostic disclosure of MCI, as well as treatment and follow-up in MCI.Results: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre- and postbiomarker counseling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI.Conclusions: The variability in clinical practices across centers calls for better biomarker counseling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning.
KW - mild cognitive impairment
KW - dementia
KW - diagnostic disclosure
KW - biomarker counselling
KW - biomarkers
KW - Alzheimer's disease
KW - survey
KW - diagnosis
KW - biomarker counseling
UR - http://www.scopus.com/inward/record.url?scp=85090978657&partnerID=8YFLogxK
U2 - 10.1002/gps.5427
DO - 10.1002/gps.5427
M3 - Article
C2 - 32896040
SN - 0885-6230
VL - 36
SP - 324
EP - 333
JO - International Journal of Geriatric Psychiatry
JF - International Journal of Geriatric Psychiatry
IS - 2
ER -
